- Home
- OBIO vs RDIB Comparison
OBIO vs RDIB Comparison
Compare OBIO & RDIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OBIO | RDIB |
|---|---|---|
| Founded | 2017 | 1937 |
| Country | United States | United States |
| Employees | N/A | 2025 |
| Industry | Medicinal Chemicals and Botanical Products | Movies/Entertainment |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 240.7M | 224.9M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | OBIO | RDIB |
|---|---|---|
| Price | $3.92 | $8.51 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $14.25 | N/A |
| AVG Volume (30 Days) | ★ 535.0K | 4.1K |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.13 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $33,482,000.00 | N/A |
| Revenue This Year | N/A | $16.25 |
| Revenue Next Year | $12.43 | $4.04 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1169.22 | N/A |
| 52 Week Low | $2.20 | $8.10 |
| 52 Week High | $5.42 | $17.40 |
Technical Indicators
Market Signals| Indicator | OBIO | RDIB |
|---|---|---|
| Relative Strength Index (RSI) | 45.34 | 41.27 |
| Support Level | $3.47 | N/A |
| Resistance Level | $4.18 | $12.53 |
| Average True Range (ATR) | 0.28 | 0.48 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 12.53 | 17.90 |
Price Performance
Historical ComparisonAbout OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.
About RDIB Reading International Inc Class B
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.